» Articles » PMID: 20304630

Extracellular Matrix: a Gatekeeper in the Transition from Dormancy to Metastatic Growth

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2010 Mar 23
PMID 20304630
Citations 200
Authors
Affiliations
Soon will be listed here.
Abstract

Metastases can develop after apparently successful treatment of a primary tumour, sometimes following a period of tumour dormancy that can last for years. However, factors that regulate metastatic tumour dormancy remain poorly understood. Here we review the potential contribution of interactions between tumour cells and the microenvironment in metastatic sites, in regulating tumour dormancy vs. metastatic growth. We focus particularly on the potential role of the extracellular matrix (ECM) in regulating maintenance and release from dormancy. Tumour cells that fail to properly adhere to the ECM may enter a state of dormancy. The molecular and physical composition of the ECM can be affected by tumour cells themselves, as well as multiple stromal cell types. The roles of integrins, fibronectin, and collagen are discussed, as are factors that can change the ECM. A better understanding of the molecular details of the crosstalk between tumour cells and the ECM in secondary sites, and how these regulate the dormant state, may lead to improved therapeutic strategies to induce or maintain disseminated tumour cells in a dormant state, or alternatively to successfully eradicate dormant cells.

Citing Articles

Tumor dormancy and relapse: understanding the molecular mechanisms of cancer recurrence.

Tufail M, Jiang C, Li N Mil Med Res. 2025; 12(1):7.

PMID: 39934876 PMC: 11812268. DOI: 10.1186/s40779-025-00595-2.


Acellular dermal matrices in reconstructive surgery; history, current implications and future perspectives for surgeons.

Dilek O, Sevim K, Dilek O World J Clin Cases. 2024; 12(35):6791-6807.

PMID: 39687641 PMC: 11525903. DOI: 10.12998/wjcc.v12.i35.6791.


Implication of the Extracellular Matrix in Metastatic Tumor Cell Dormancy.

Redoute-Timonnier C, Auguste P Cancers (Basel). 2024; 16(23).

PMID: 39682261 PMC: 11639913. DOI: 10.3390/cancers16234076.


Advanced biomaterials for regenerative medicine and their possible therapeutic significance in treating COVID-19: a critical overview.

Sarangi A, Salem M, Younus M, El-Haroun H, Mahal A, Tripathy L Int J Surg. 2024; 110(12):7508-7527.

PMID: 39411890 PMC: 11634172. DOI: 10.1097/JS9.0000000000002110.


Inflammation drives tumor growth in an immunocompetent implantable metastasis model.

Giles C, Lee J Res Sq. 2024; .

PMID: 39149496 PMC: 11326373. DOI: 10.21203/rs.3.rs-4719290/v1.


References
1.
Tlsty T, Coussens L . Tumor stroma and regulation of cancer development. Annu Rev Pathol. 2007; 1:119-50. DOI: 10.1146/annurev.pathol.1.110304.100224. View

2.
Hasebe T, Sasaki S, Imoto S, Mukai K, Yokose T, Ochiai A . Prognostic significance of fibrotic focus in invasive ductal carcinoma of the breast: a prospective observational study. Mod Pathol. 2002; 15(5):502-16. DOI: 10.1038/modpathol.3880555. View

3.
Naumov G, MacDonald I, Weinmeister P, Kerkvliet N, Nadkarni K, Wilson S . Persistence of solitary mammary carcinoma cells in a secondary site: a possible contributor to dormancy. Cancer Res. 2002; 62(7):2162-8. View

4.
Teng M, Swann J, Koebel C, Schreiber R, Smyth M . Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol. 2008; 84(4):988-93. DOI: 10.1189/jlb.1107774. View

5.
Chang H, Sneddon J, Alizadeh A, Sood R, West R, Montgomery K . Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds. PLoS Biol. 2004; 2(2):E7. PMC: 314300. DOI: 10.1371/journal.pbio.0020007. View